KRAS and neoplasm: In our cohort, 28 of 83 (34%) patients had BRAF V600Mx, KRAS Mx, NRAS G12/G13 and/or NRAS Q61 mutations in their bone marrow tumor DNA sample (4 [5%] BRAF V600Mx mutations, 13 [16%] KRAS Mx mutations, 3 [4%] NRAS G12/G13 mutations, 14 [17%] NRAS Q61 mutations).